In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Novartis (NVS – Research Report), with a price target of ...

NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 ...

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...

The Max Foundation expands collaboration with Novartis to include access to innovative treatment for paroxysmal nocturnal hemoglobinuria: Seattle, Washington Monday, December 9, 2 ...

New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...

Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...

Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...

The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.

Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...

Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood ...